Quarterly report · Q2
2796.TEDINET S100SLC9
Period2023-06-01 → 2023-11-30
Filed2024-01-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥26.9bn | 2023-06-01 → 2023-11-30 | Cons. | Net sales |
| Revenue | ¥52.0bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥25.7bn | 2022-06-01 → 2022-11-30 | Cons. | Net sales |
| Operating income | ¥710m | 2023-06-01 → 2023-11-30 | Cons. | Operating income |
| Operating income | ¥573m | 2022-06-01 → 2022-11-30 | Cons. | Operating income |
| Ordinary income | ¥701m | 2023-06-01 → 2023-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.4bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥566m | 2022-06-01 → 2022-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥662m | 2023-06-01 → 2023-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥394m | 2022-06-01 → 2022-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥273m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥333m | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥72m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥282m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss |
| Net income | ¥77m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss |
| Total assets | ¥23.0bn | at 2023-11-30 | Cons. | Assets |
| Total assets | ¥23.4bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥23.3bn | at 2022-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥14.6bn | at 2023-11-30 | Cons. | Liabilities |
| Total liabilities | ¥16.4bn | at 2023-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.4bn | at 2023-11-30 | Cons. | Net assets |
| Net assets / equity | ¥7.0bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.9bn | at 2023-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.7bn | at 2023-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.9bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.7bn | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.3bn | at 2022-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2022-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.9bn | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.5bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.6bn | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥543m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥703m | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥448m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.1bn | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.1bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥792m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥28.29 | 2023-06-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.12 | 2023-09-01 → 2023-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.45 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.76 | 2022-06-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.08 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥26.99 | 2023-06-01 → 2023-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥26.89 | 2022-06-01 → 2023-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥5.93 | 2022-06-01 → 2022-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 35.3% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.5% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.4% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-06-01 → 2023-11-30 | ¥389m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-06-01 → 2023-11-30 | ¥389m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-06-01 → 2023-11-30 | ¥2m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2023-11-30 | −¥162m |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥4.1bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥4.1bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | segment profit | 2023-06-01 → 2023-11-30 | −¥38m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥301m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥301m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥21m |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥21.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥21.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥831m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥252m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥252m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥56m |
| —segment total | revenue | 2023-06-01 → 2023-11-30 | ¥26.6bn |
| —segment total | revenue external | 2023-06-01 → 2023-11-30 | ¥26.6bn |
| —segment total | segment profit | 2023-06-01 → 2023-11-30 | ¥870m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2023-11-30 | ¥26.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2023-11-30 | ¥26.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2023-11-30 | ¥872m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-06-01 → 2022-11-30 | ¥375m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-06-01 → 2022-11-30 | ¥375m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-06-01 → 2022-11-30 | ¥26m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2022-11-30 | −¥153m |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥3.9bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥3.9bn |
| jpcrp040300-q2r_E05379-000Cosmetic Drug And Convenience Storereportable segment | segment profit | 2022-06-01 → 2022-11-30 | −¥129m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥328m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥328m |
| jpcrp040300-q2r_E05379-000Custody Of Medical Documentsreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥38m |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥20.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥20.9bn |
| jpcrp040300-q2r_E05379-000Dispensing Pharmacyreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥744m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥252m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥252m |
| jpcrp040300-q2r_E05379-000Medical Mallreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥45m |
| —segment total | revenue | 2022-06-01 → 2022-11-30 | ¥25.4bn |
| —segment total | revenue external | 2022-06-01 → 2022-11-30 | ¥25.4bn |
| —segment total | segment profit | 2022-06-01 → 2022-11-30 | ¥699m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2022-11-30 | ¥25.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2022-11-30 | ¥25.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2022-11-30 | ¥726m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 548
| Item | Context | Value | Unit |
|---|---|---|---|
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 312000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 188000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 3991000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 4734000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 4303000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 4923000000 | JPY |
| Directors compensations sga | Prior1YTDDuration | 154000000 | JPY |
| Directors compensations sga | CurrentYTDDuration | 169000000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 553000000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 581000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 18000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 19000000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | 0 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | 3000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 78000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 90000000 | JPY |
| Taxes and dues sga | Prior1YTDDuration | 1202000000 | JPY |
| Taxes and dues sga | CurrentYTDDuration | 1183000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05379-000DispensingPharmacyReportableSegmentsMember | 20932000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05379-000CosmeticDrugAndConvenienceStoreReportableSegmentsMember | 3857000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05379-000CustodyOfMedicalDocumentsReportableSegmentsMember | 328000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05379-000MedicalMallReportableSegmentsMember | 252000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 25370000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 375000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 25745000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 25745000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05379-000DispensingPharmacyReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05379-000CosmeticDrugAndConvenienceStoreReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05379-000CustodyOfMedicalDocumentsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05379-000MedicalMallReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05379-000DispensingPharmacyReportableSegmentsMember | 20932000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05379-000CosmeticDrugAndConvenienceStoreReportableSegmentsMember | 3857000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05379-000CustodyOfMedicalDocumentsReportableSegmentsMember | 328000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05379-000MedicalMallReportableSegmentsMember | 252000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 25370000000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 375000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 25745000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 25745000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05379-000DispensingPharmacyReportableSegmentsMember | 744000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05379-000CosmeticDrugAndConvenienceStoreReportableSegmentsMember | -129000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05379-000CustodyOfMedicalDocumentsReportableSegmentsMember | 38000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05379-000MedicalMallReportableSegmentsMember | 45000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 699000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |